Latest Insider Transactions at Mirati Therapeutics, Inc. (MRTX)
This section provides a real-time view of insider transactions for Mirati Therapeutics, Inc. (MRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mirati Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mirati Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 14
2022
|
Bruce L A Carter |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|
|
Jan 14
2022
|
Faheem Hasnain |
BUY
Grant, award, or other acquisition
|
Direct |
3,619
+29.34%
|
-
|
|
Jan 14
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,755
+23.2%
|
-
|
|
Jan 14
2022
|
Charles M Baum Founder, President, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,543
+16.78%
|
-
|
|
Jan 14
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,755
+10.88%
|
-
|
|
Jan 14
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,377
+25.27%
|
-
|
|
Jan 07
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
345
-3.17%
|
$46,575
$135.94 P/Share
|
|
Jan 07
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,964
-7.33%
|
$265,140
$135.94 P/Share
|
|
Jan 04
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
758
-6.52%
|
$111,426
$147.74 P/Share
|
|
Jan 04
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,442
-1.83%
|
$211,974
$147.72 P/Share
|
|
Jan 04
2022
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
4,114
-1.96%
|
$608,872
$148.41 P/Share
|
|
Dec 16
2021
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,149
+19.56%
|
-
|
|
Dec 16
2021
|
Charles M Baum Founder, President, and CEO |
SELL
Bona fide gift
|
Direct |
7,430
-6.59%
|
-
|
|
Dec 06
2021
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,201
-0.99%
|
$157,331
$131.39 P/Share
|
|
Dec 03
2021
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,856
+10.15%
|
-
|
|
Dec 03
2021
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
47,204
-4.78%
|
$6,325,336
$134.54 P/Share
|
|
Dec 03
2021
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,204
+22.79%
|
$377,632
$8.49 P/Share
|
|
Jun 18
2021
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
40,000
-7.14%
|
$6,600,000
$165.44 P/Share
|
|
Jun 18
2021
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+20.76%
|
$320,000
$8.49 P/Share
|
|
May 24
2021
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
435
-0.8%
|
$66,990
$154.34 P/Share
|
|
Apr 05
2021
|
Bruce L A Carter |
SELL
Open market or private sale
|
Direct |
2,250
-20.94%
|
$400,500
$178.35 P/Share
|
|
Apr 05
2021
|
Bruce L A Carter |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+28.21%
|
$13,500
$6.78 P/Share
|
|
Mar 26
2021
|
Shalini Sharp |
BUY
Grant, award, or other acquisition
|
Direct |
2,424
+50.0%
|
-
|
|
Mar 19
2021
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,369
-2.77%
|
$416,944
$176.56 P/Share
|
|
Mar 19
2021
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,369
+7.51%
|
$270,066
$114.33 P/Share
|
|
Mar 10
2021
|
Braslyn Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
410
-0.0%
|
$80,360
$196.38 P/Share
|
|
Mar 10
2021
|
Braslyn Ltd. > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
410
+0.01%
|
-
|
|
Mar 09
2021
|
Braslyn Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
11,971
-0.08%
|
$2,346,316
$196.2 P/Share
|
|
Mar 09
2021
|
Braslyn Ltd. > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
11,971
+0.38%
|
-
|
|
Mar 05
2021
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
400,005
-7.3%
|
$72,400,905
$181.07 P/Share
|
|
Mar 05
2021
|
Boxer Capital, LLC |
BUY
Exercise of conversion of derivative security
|
Direct |
611,440
+12.58%
|
-
|
|
Mar 02
2021
|
Julie M Cherrington |
SELL
Open market or private sale
|
Direct |
2,000
-28.97%
|
$404,000
$202.0 P/Share
|
|
Feb 02
2021
|
Bruce L A Carter |
SELL
Open market or private sale
|
Direct |
2,250
-14.56%
|
$432,000
$192.4 P/Share
|
|
Feb 02
2021
|
Bruce L A Carter |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+28.21%
|
$13,500
$6.78 P/Share
|
|
Feb 02
2021
|
Daniel Faga EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,340
-4.19%
|
$259,960
$194.38 P/Share
|
|
Feb 02
2021
|
Daniel Faga EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,340
+4.02%
|
$152,760
$114.33 P/Share
|
|
Jan 29
2021
|
Maria E Martinez |
SELL
Open market or private sale
|
Direct |
7,500
-10.55%
|
$1,515,000
$202.61 P/Share
|
|
Jan 29
2021
|
Maria E Martinez |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+40.6%
|
$292,500
$39.76 P/Share
|
|
Jan 26
2021
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,292
+1.99%
|
$11,460
$5.4 P/Share
|
|
Jan 21
2021
|
Craig A Johnson |
SELL
Open market or private sale
|
Direct |
15,000
-22.59%
|
$3,180,000
$212.35 P/Share
|
|
Jan 21
2021
|
Craig A Johnson |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+44.81%
|
$300,000
$20.54 P/Share
|
|
Jan 19
2021
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,245
+2.85%
|
$87,615
$27.0 P/Share
|
|
Jan 15
2021
|
Daniel Faga EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,023
+18.65%
|
-
|
|
Jan 15
2021
|
Faheem Hasnain |
BUY
Grant, award, or other acquisition
|
Direct |
2,098
+29.16%
|
-
|
|
Jan 15
2021
|
Aaron I. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+3.51%
|
-
|
|
Jan 15
2021
|
Julie M Cherrington |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Craig A Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Michael G Grey |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+20.47%
|
-
|
|
Jan 15
2021
|
Henry J Fuchs |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Maria E Martinez |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|